Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag

Catalog Number: AVI11377

DESCRIPTION

Source

Human embryonic kidney cell, HEK293-derived human 5'-Nucleotidase/CD73 protein



N-terminal Sequence Analysis	Trp27
Structure / Form	Biotinylated via Avi-tag
Predicted Molecular Mass	86 kDa

SPECIFICATIONS

SDS-PAGE	88-98 kDa, under reducing conditions
Activity	Measured by its ability to hydrolyze the 5'-phosphate group from the substrate adenosine-5'-monophosphate (AMP). The orthophosphate product is measured by a Malachite Green Phosphate Detection Kit (Catalog # DY996). The specific activity is >5500 pmol/min/µg, as measured under the described conditions. Measured by its binding ability in a functional ELISA. Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag (Catalog # AVI11377) binds Human/Equine 5'-Nucleotidase/CD73 Antibody (Catalog # MAB5795) with an ED_{50} of 3.00-30.0 ng/mL.
Endotoxin Level	<1.0 EU per 1 µg of the protein by the LAL method.
Purity	>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation	Supplied as a 0.2 µm filtered solution in Tris, NaCl, $CaCl_2$ and Glycerol. See Certificate of Analysis for details.

Activity Assay Protocol

Materials

- Assay Buffer: 25 mM Tris, 5 mM $MgCl_2$, pH 7.5
- Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag (rhCD73/Fc) (Catalog # AVI11397)
- Substrate: Adenosine monophosphate (AMP), 5 mM stock in deionized water
- Malachite Green Phosphate Detection Kit (Catalog # DY996)
- 96-well Clear Plate (Catalog # DY990)
- Plate Reader with Absorbance Read Capability

Assay

1. Prepare a standard curve from the 1 M Phosphate Standard by adding 10 µL of the 1 M Phosphate Standard to 990 µL of Assay Buffer for a 10 mM stock. Continue by adding 10 µL of the 10 mM Phosphate stock to 990 µL of Assay Buffer for a 100 µM stock (this is the first dilution to use as a standard).
2. Perform six additional one-half serial dilutions of the 100 µM Phosphate stock using Assay Buffer. The standard curve has a range of 0.078 to 5 nmol per well.
3. Dilute rhCD73/Fc to 0.16 µg/mL in Assay Buffer.
4. Dilute AMP to 100 µM in Assay Buffer.
5. Load 50 µL of each dilution of the standard curve into a plate. Include a curve blank containing 50 µL of Assay Buffer.
6. Load 25 µL of 0.16 µg/mL rhCD73/Fc into empty wells of the same plate as the curve. Include a Control containing 25 µL of Assay Buffer.
7. Start the reactions by adding 25 µL of 100 µM AMP to all wells, excluding the standard curve and curve blank.
8. Seal plate and incubate at 37 °C for 20 minutes.
9. Add 30 µL of the Malachite Green Reagent A to all wells used, including standard curve. Mix briefly.
10. Add 100 µL of deionized water to all wells used, including standard curve. Mix briefly.
11. Add 30 µL of the Malachite Green Reagent B to all wells used, including standard curve. Mix briefly.
12. Seal plate and incubate at room temperature for 20 minutes.
13. Read plate at 620 nm (absorbance) in endpoint mode.
14. Calculate specific activity:

$$\text{Specific Activity (pmol/min/µg)} = \frac{\text{Phosphate released* (nmol) x (1000 pmol/nmol)}}{\text{Incubation time (min) x amount of enzyme (µg)}}$$

*Derived from the phosphate standard curve using linear or 4-parameter fitting and adjusted for Control.

Final Assay Conditions

Per Reaction:

- rhCD73/Fc: 0.004 µg
- Substrate: 50 µM

Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449

Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag

Catalog Number: AVI11377

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	**Use a manual defrost freezer and avoid repeated freeze-thaw cycles.** • 6 months from date of receipt, -20 to -70 °C as supplied. • 3 months, -20 to -70 °C under sterile conditions after opening.

DATA

Binding Activity



Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag Protein Binding Activity. Biotinylated Recombinant Human 5'-Nucleotidase/CD73 Fc Chimera Avi-tag Protein (Catalog # AVI11377) binds Human/Equine 5'-Nucleotidase/CD73 Antibody (Catalog # MAB5795) with an ED_{50} of 3.00-30.0 ng/mL.

BACKGROUND

CD73, known as ecto-5'-Nucleotidase, converts extracellular nucleoside 5' monophosphates to nucleosides, with AMP as its preferred substrate (1). CD73 is a zinc-dependent, homodimeric enzyme bound to the cell membrane through a glycosyl phosphatidylinositol (GPI) anchor. It is composed of an N-terminal domain containing metal binding sites linked via small hinge region to a C-terminal domain containing the substrate binding site and dimerization interface (2). It is expressed by most cell types (3) and is widely expressed in tumor cell lines as well as upregulated in cancerous tissues (4, 5). CD73 is a key enzyme responsible for a rate-limiting step in the generation of extracellular adenosine. Adenosine is a molecule that signals through activation of purinergic receptors and results in an immunosuppressive role in the tumor microenvironment (4, 6). CD73 has been implicated in many pathological processes including immunomodulation and inflammation (7,8) tumor growth and metastasis (9-13) making CD73 a potential drug target in cancer. Targeting CD73 inhibition has resulted in numerous reports of favorable antitumor effects (4, 5, 12). Consequently, therapeutic approaches have been tested using knockdown, gene silencing and anti-CD73 therapies (11, 14) as well as small molecule inhibitors (14, 15).

References:

1. Zimmermann, H. *et. al.* (2012) Purinergic Signal. **8**:437.
2. Knapp, K. *et. al.* (2012) Structure. **20**:2161.
3. Resta, R. *et. al.* (1998) Immunol. Rev. **161**:95.
4. Jin, D. *et. al.* (2010) Cancer Res. **70**:2245.
5. Zhang, B. (2010) Cancer Res. **70**:6407.
6. Picher, M. *et. al.* (2003) J. Biol. Chem. **278**:13468.
7. Antonioli, L. *et. al.* (2012) Curr. Drug Targets **13**:842.
8. Eltzchig, H.K. *et. al.* (2012) N. Engl. J. Med. **367**:2322.
9. Bavaresco, L. *et. al.* (2008) Mol. Cell Biochem. **319**:61.
10. Yegutkin, G.G. *et. al.* (2011) Eur. J. Immunol. **41**:1231.
11. Stagg, J. *et. al.* (2012) Cancer Res. **72**:2190.
12. Ghalamfarsa, G. *et. al.* (2019) Expert Opin. Ther. Targets. **23**:127.
13. Gao, Z.W. *et. al.* (2014) Biomed. Res. Int. **2014**:460654.
14. Young, A. *et. al.* (2014) Cancer Discov. **4**:879.
15. McManus, J. *et. al.* (2018) SLAS Discov. **23**:264.

Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956
USA TEL 800 343 7475 **Canada** TEL 855 668 8722 **China** TEL +86 (21) 52380373
Europe | Middle East | Africa TEL +44 (0)1235 529449